mRNA Synthesis Raw Materials Market Share Analysis Report, 2023-2032
The global mRNA synthesis raw materials market size was exhibited at USD 3.98 billion in 2022 and is projected to hit around USD 5 billion by 2032, growing at a CAGR of 2.3% during the forecast period 2023 to 2032.
Key Pointers:
mRNA Synthesis Raw Materials Market Report Scope
|
Report Coverage |
Details |
|
Market Size in 2023 |
USD 4.07 Billion |
|
Market Size by 2032 |
USD 5 Billion |
|
Growth Rate from 2023 to 2032 |
CAGR of 2.3% |
|
Base year |
2022 |
|
Forecast period |
2023 to 2032 |
|
Segments covered |
Type, Application, End-user, |
|
Regional scope |
North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
|
Key companies profiled |
F. Hoffmann-La Roche Ltd.; Jena Bioscience GmbH; Merck KGaA; Yeasen Biotechnology (Shanghai) Co., Ltd.; BOC Sciences; Thermo Fisher Scientific, Inc.: Maravai LifeSciences; New England Biolabs; Creative Biogene; HONGENE |
The major factors driving the market growth include growing academic and industrial interest in mRNA technology, the advantages of mRNA vaccines, and increasing funding for research. In addition, the increasing therapeutic applications of RNA technology are projected to offer lucrative opportunities for the mRNA synthesis raw materials market during the forecast period.
The COVID-19 pandemic has increased the demand for mRNA synthesis raw materials for developing an efficient vaccine to battle infectious diseases. mRNA vaccines are a safe and efficient method for preventing COVID-19. In addition, the advantages associated with the mRNA COVID-19 vaccines have sparked the attention of pharmaceutical businesses in delivering vaccines swiftly across the globe. For instance, the National Institute of Allergy and Infectious Diseases and Moderna, Inc. mutually developed the mRNA-1273 (NIAID) in March 2020. As a result, the usage of mRNA vaccines increased significantly during the COVID-19 pandemic.
Furthermore, many major pharmaceutical firms have started working on mRNA-based therapeutics, including Novartis, Alexion, AstraZeneca, Pfizer, Sanofi Pasteur, and Shire. For instance, in January 2022, according to a development and option agreement between Pfizer Inc. and Acuitas Therapeutics, Pfizer will have the option to license Acuitas' LNP technology for up to 10 targets for the development of mRNA therapeutics & vaccines. Therefore, the adoption rate of mRNA synthesis raw materials has increased among pharma & biotech companies, which further fuels the market growth.
Moreover, due to the temporary nature of mRNA translation and lack of integration of the foreign material into the cell's genome, the resulting cellular therapeutic product has a number of benefits over the one obtained by a more conventional approach. Some of the advantages include easier production under acceptable manufacturing procedures, reduced cytotoxicity from on-target off-tumor effects, and better clinical validation and regulatory treatment. Thus, such advantages are expected to increase the demand for mRNA therapeutics and further boost market growth.
Additionally, regarding the treatment and prevention of several diseases, mRNA-based technologies have been proven to be incredibly promising. Tremendous advances in technology and scientific study over the past ten years have made mRNA a feasible therapeutic option, eliminating some of the problems with its use, such as its brief half-life and innate immunogenicity. For instance, as mRNA technology advances, its fusion with new adoptive immunotherapies may result in safer and more efficient methods, such as the creation of cutting-edge chimeric antigen receptor T-cells. Therefore, advancements in mRNA technology are projected to open new avenues for market growth.
However, the high cost of raw materials may impede the market during the study period. For instance, the purchase price of raw materials, such as CleanCap AG, accounts for around 45% of the total raw material costs incurred while producing both vaccines. In addition, the regulatory framework pertaining to approval processes has always been the most critical restraining factor in the biotechnology, pharmaceutical, and medical technology industry. The absence of effective regulatory framework/guidelines for the therapeutic sector in developing countries such as China and India, where the mRNA synthesis raw materials market holds great growth potential due to the presence of a large patient base, is anticipated to impede the market growth in the coming years.
Type Insights
In 2022, the capping agents segment dominated the global industry, accounting for 40.75% of total revenue. Capping and tailing are important steps in the production of active mRNA for use in functional studies. In eukaryotes, these steps prevent degradation and facilitate translation. Capping agents function as binding molecules or stabilizers, preventing steric hindrance or agglomeration. Hence, the key functions of capping agents in mRNA synthesis are driving segment growth.
Furthermore, the capping agents segment is anticipated to expand at the fastest CAGR of 2.27% during the forecast period. This can be attributed to the development of modern alternatives to the enzymatic capping of mRNA. Key players in the market are developing capping technology for industries to support the development of mRNA therapeutics and vaccines. For instance, TriLink developed CleanCap technology that offers GMP-grade CleanCap reagents. These reagents help to develop 5’ Cap1 mRNA with 95% efficiency in a quick and easiest method. As a result, the continuous advancements of capping technology are anticipated to boost segment growth and fuel the market.
Application Insights
The vaccine production segment held the largest market share of 85.9% in 2022 in terms of revenue. This can be attributed to the rapid production of mRNA vaccines compared to the conventional vaccines that utilize cell-culture-based production paths, which are often prone to failure. Moreover, advancements in mRNA, coupled with the need to ramp up production capacity to meet global demand, are providing opportunities to build flexible vaccine manufacturing facilities globally. For instance, in December 2022, the construction of a large-scale mRNA manufacturing facility commenced in Australia. The facility is expected to be operational in 2024 and aims to produce up to 100 million doses of vaccine annually for respiratory diseases caused by viruses such as influenza and respiratory syncytial virus. Hence, such increasing demand for vaccines is driving the need for raw materials, thereby boosting market growth.
The therapeutics production segment is expected to expand at the fastest CAGR of 2.99% during 2023-2032, due to the increasing prevalence of various chronic and infectious diseases. For instance, according to WHO, about 10.6 million people worldwide contracted tuberculosis in 2021 (1.2 million children, 6 million men, & 3.4 million women). mRNA-based therapeutics not only present promising treatment strategies for several diseases but also helps in prevention. Hence, there is an increase in clinical trials and in vivo models to produce various therapeutics based on mRNA platforms, which is likely to aid revenue generation in this segment.
End-user Insights
The biopharmaceutical and pharmaceutical companies segment dominated the market and accounted for the highest revenue share of 49.19% in 2022, due to the high commercial success of biopharmaceuticals and rapid growth in demand for therapeutics. Significant growth in the pharmaceutical industry pipeline has boosted the need for mRNA synthesis raw materials for the discovery of novel therapeutics. For instance, according to data from Informa, Moderna is the company with the most mRNA drugs in the pipeline with 46 drugs, followed by BioNTech with 29, CureVac with 19, Sanofi with 11, Pfizer with 10, GSK with 5, and AstraZeneca with 4.
Moreover, the biopharmaceutical and pharmaceutical segment is also expected to expand at a rapid pace during 2023-2032, owing to the increasing approvals of mRNA-based vaccines. For instance, in August 2022, a bivalent COVID-19 vaccine developed by Moderna, Pfizer-BioNTech received approval from the FDA for use as a booster dose. Thus, increasing focus on pipeline and government approvals by biopharmaceutical & pharmaceutical companies is significantly increasing the demand for these raw materials and contributing to segment growth.
Regional Insights
North America captured the largest market share of 35.19% in 2022, owing to the presence of an established biopharmaceutical and CRO industry in the region, as well as a high extent of R&D activities. In addition, the local presence of operating players such as BOC Sciences, Maravai LifeSciences, and New England Biolabs, among others, is expected to further drive the market in the region.
Furthermore, The North American region is also projected to expand at the fastest CAGR by 2032. This can be attributed to the increasing number of clinical trials, availability of research funding, and expanding federal programs toward RNA-based medicines in the region due to the COVID-19 pandemic, which has positively affected the market in North America.
Some of the prominent players in the MRNA Synthesis Raw Materials Market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2032. For this study, Nova one advisor, Inc. has segmented the global mRNA Synthesis Raw Materials market.
By Type
By Application
By End-use
By Region
Chapter 1 Methodology and Scope
1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates And Forecast Timeline
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Nova one advisor’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Market Variables, Trends, & Scope
3.1 Parent Market Analysis
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Growing Academic And Industrial Interest In mRNA Technology
3.2.1.2 Advantages Of mRNA Vaccines
3.2.1.3 Increasing Funding For mRNA Research
3.2.2 Market Restraint Analysis
3.2.2.1 Nonexistence Of Effective Government Regulations For mRNA - Based Product Approvals
3.2.2.2 High Cost Of mRNA Synthesis Raw Materials
3.2.3 Market Challange Analysis
3.2.3.1 Lack Of Long - Lasting And Affordable Manufacturing Processes
3.3 Penetration &Growth Prospect Mapping
3.4 mRNA Synthesis Raw Materials Market - Porter’s Analysis
3.5 mRNA Synthesis Raw Materials Market - Swot Analysis
3.6 Covid - 19 Impact Analysis
Chapter 4 Type Business Analysis
4.1 mRNA Synthesis Raw Materials Market - Type Movement Analysis
4.2 Capping Agents
4.2.1 Global Capping Agents Market, 2020 - 2032
4.3 Nucleotides
4.3.1 Global Nucleotides Market, 2020 - 2032
4.4 Plasmid Dna
4.4.1 Global Plasmid Dna Market, 2020 - 2032
4.5 Others
4.5.1 Global Other Types Market, 2020 - 2032
Chapter 5 Application Business Analysis
5.1 mRNA Synthesis Raw Materials Market - Application Movement Analysis
5.2 Therapeutics Production
5.2.1 Global Therapeutics Production Market, 2020 - 2032
5.3 Vaccine Production
5.3.1 Global Vaccine Production Market, 2020 - 2032
5.4 Others
5.4.1 Global Other Applications Market, 2020 - 2032
Chapter 6 End - User Business Analysis
6.1 mRNA Synthesis Raw Materials Market - End User Movement Analysis
6.2 Biopharmaceutical & Pharmaceutical Companies
6.2.1 Global Biopharmaceutical & Pharmaceutical Companies, 2020 - 2032
6.3 Cros & Cmos
6.3.1 Global Cros & Cmos, 2020 - 2032
6.4 Academic And Research Institutions
6.4.1 Global Academic And Research Institutions, 2020 - 2032
Chapter 7 Regional Business Analysis
7.1 mRNA Synthesis Raw Materials Market: Regional Movement Analysis
7.2 North America
7.2.1 Swot Analysis
7.2.1.1 North America mRNA Synthesis Raw Materials Market, 2020 - 2032
7.2.2 U.S.
7.2.2.1 Key Country Dynamics
7.2.2.2 Competitive Scenario
7.2.2.3 Regulatory Framework
7.2.2.4 U.S. mRNA Synthesis Raw Materials Market, 2020 - 2032
7.2.3 Canada
7.2.3.1 Key country dynamics
7.2.3.2 Competitive scenario
7.2.3.3 Regulatory framework
7.2.3.4 Canada mRNA synthesis raw materials market, 2020 - 2032
7.3 Europe
7.3.1 Swot Analysis
7.3.1.1 Europe mRNA Synthesis Raw Materials Market Estimates And Forecast, 2020 - 2032
7.3.2 Germany
7.3.2.1 Key Country Dynamics
7.3.2.2 Competitive Scenario
7.3.2.3 Regulatory Framework
7.3.2.4 Germany mRNA Synthesis Raw Materials Market, 2020 - 2032
7.3.3 U.K.
7.3.3.1 Key Country Dynamics
7.3.3.2 Competitive Scenario
7.3.3.3 Regulatory Framework
7.3.3.4 Uk mRNA Synthesis Raw Materials Market, 2020 - 2032
7.3.4 France
7.3.4.1 Key Country Dynamics
7.3.4.2 Competitive Scenario
7.3.4.3 Regulatory Framework
7.3.4.4 France mRNA Synthesis Raw Materials Market, 2020 - 2032
7.3.5 Italy
7.3.5.1 Key Country Dynamics
7.3.5.2 Competitive Scenario
7.3.5.3 Regulatory Framework
7.3.5.5 Italy mRNA Synthesis Raw Materials Market, 2020 - 2032
7.3.6 Spain
7.3.6.1 Key Country Dynamics
7.3.6.2 Competitive Scenario
7.3.6.3 Regulatory Framework
7.3.6.4 Spain mRNA Synthesis Raw Materials Market, 2020 - 2032
7.3.7 Denmark
7.3.7.1 Key Country Dynamics
7.3.7.2 Competitive Scenario
7.3.7.3 Regulatory Framework
7.3.7.4 Denmark mRNA Synthesis Raw Materials Market, 2020 - 2032
7.3.8 Sweden
7.3.8.1 Key Country Dynamics
7.3.8.2 Competitive Scenario
7.3.8.3 Regulatory Framework
7.3.8.4 Sweden mRNA Synthesis Raw Materials Market, 2020 - 2032
7.3.9 Norway
7.3.9.1 Key country dynamics
7.3.9.2 Competitive scenario
7.3.9.3 Regulatory framework
7.3.9.4 Norway mRNA synthesis raw materials market, 2020 - 2032
7.4 Asia Pacific
7.4.1 Swot Analysis
7.4.1.1 Asia Pacific mRNA Synthesis Raw Materials, 2020 - 2032
7.4.2 Japan
7.4.2.1 Key Country Dynamics
7.4.2.2 Competitive Scenario
7.4.2.3 Regulatory Framework
7.4.2.4 Japan mRNA Synthesis Raw Materials Market, 2020 - 2032
7.4.3 China
7.4.3.1 Key Country Dynamics
7.4.3.2 Competitive Scenario
7.4.3.3 Regulatory Framework
7.4.3.4 China mRNA Synthesis Raw Materials Market, 2020 - 2032
7.4.4 India
7.4.4.1 Key Country Dynamics
7.4.4.2 Competitive Scenario
7.4.4.3 Regulatory Framework
7.4.4.4 India mRNA Synthesis Raw Materials Market, 2020 - 2032
7.4.5 Australia
7.4.5.1 Key Country Dynamics
7.4.5.2 Competitive Scenario
7.4.5.3 Regulatory Framework
7.4.5.4 Australia mRNA Synthesis Raw Materials Market, 2020 - 2032
7.4.6 South Korea
7.4.6.1 Key Country Dynamics
7.4.6.2 Competitive Scenario
7.4.6.3 Regulatory Framework
7.4.6.4 South Korea mRNA Synthesis Raw Materials Market, 2020 - 2032
7.4.7 Thailand
7.4.7.1 Key country dynamics
7.4.7.2 Competitive scenario
7.4.7.3 Regulatory framework
7.4.7.4 Thailand mRNA synthesis raw materials market, 2020 - 2032
7.5 Latin America
7.5.1 Swot Analysis
7.5.1.1 Latin America mRNA Synthesis Raw Materials Market, 2020 - 2032
7.5.2 Brazil
7.5.2.1 Key Country Dynamics
7.5.2.2 Competitive Scenario
7.5.2.3 Regulatory Framework
7.5.2.4 Brazil mRNA Synthesis Raw Materials Market, 2020 - 2032
7.5.3 Mexico
7.5.3.1 Key Country Dynamics
7.5.3.2 Competitive Scenario
7.5.3.3 Regulatory Framework
7.5.3.4 Mexico mRNA Synthesis Raw Materials Market, 2020 - 2032
7.5.4 Argentina
7.5.4.1 Key country dynamics
7.5.4.2 Competitive scenario
7.5.4.3 Regulatory framework
7.5.4.4 Argentina mRNA synthesis raw materials market, 2020 - 2032
7.6 Middle East & Africa
7.6.1 Swot Analysis
7.6.1.1 Mea mRNA Synthesis Raw Materials Market Estimates And Forecast, 2020 - 2032
7.6.2 South Africa
7.6.2.1 Key country dynamics
7.6.2.2 Competitive scenario
7.6.2.3 Regulatory framework
7.6.2.4 South Africa mRNA synthesis raw materials market estimates and forecast, 2020 - 2032
7.6.3 Saudi Arabia
7.6.3.1 Key country dynamics
7.6.3.2 Competitive scenario
7.6.3.3 Regulatory framework
7.6.3.4 Saudi Arabia mRNA synthesis raw materials market estimates and forecast, 2020 - 2032
7.6.4 UAE
7.6.4.1 Key country dynamics
7.6.4.2 Competitive scenario
7.6.4.3 Regulatory framework
7.6.4.4 UAE mRNA synthesis raw materials market estimates and forecast, 2020 - 2032
7.6.5 KUWAIT
7.6.5.1 Key country dynamics
7.6.5.2 Competitive scenario
7.6.5.3 Regulatory framework
7.6.5.4 Kuwait mRNA synthesis raw materials market estimates and forecast, 2020 - 2032
Chapter 8 Competitive Landscape
8.1 Participant’s Overview
8.1.1 F. Hoffmann - La Roche Ltd.
8.1.2 Jena Bioscience Gmbh
8.1.3 Merck KGaA
8.1.4 Yeasen Biotechnology (Shanghai) Co.,Ltd.
8.1.5 BOC Sciences
8.1.6 Thermo Fisher Scientific, Inc.
8.1.7 Maravai Lifesciences
8.1.8 New England Biolabs
8.1.9 Creative Biogene
8.1.10 Hongene
8.2 Financial Performance
8.3 Participant Categorization
8.3.1 Market Leaders
8.3.1.1 mRNA Synthesis Raw Materials Market Share Analysis, 2023
8.3.2 Strategy Mapping
8.3.2.1 Expansion
8.3.2.2 Acquisition
8.3.2.3 Collaborations
8.3.2.4 Product/service launch
8.3.2.5 Partnerships
8.3.2.6 Others
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers